Conditions

  An obesity classification system that distinguishes between fat and lean tissue and takes into account functional status and the various comorbid conditions that can be associated with obesity may be a more effective mortality prediction tool than standard body mass index (BMI), according to new research.…

Having more muscle mass can protect against insulin resistance and prediabetes, no matter overall body size, researchers said.… In a cross-sectional study, every 10% increase in the ratio of skeletal muscle mass to total body weight was associated with an 11% reduction in risk of insulin resistance and a 12% …

Optimum screening cut-offs for HbA1c in emergency setting similar to outpatient care….

Edited by Trisha Dunning AM, RN, MEd, PhD, CDE, FRCNA and Glenn Ward MBBS, BSc, DPhil (Oxon), FRACP, FRCPath Mrs. ORA was referred to a diabetes educator when she developed diabetes at 29.5 weeks’ gestation. Mrs. ORA is a 30-year-old primigravida and is 29.5 weeks pregnant. She was referred to the …

Discovery makes white fat mimic energy-burning brown fat, muscle.…

Exenatide, a GLP-1 receptor agonist, improves glycemic control and body weight with twice daily or once weekly subcutaneous (SC) injections in patients with type 2 diabetes (T2DM)….

Type 2 diabetes mellitus (T2DM) often requires combination therapy to maintain glycemic control. Adding a sulfonylurea to metformin therapy improves glycemic control, but can cause hypoglycemia and weight gain. This 2-yr double-blind trial investigated the long-term efficacy and safety of adding linagliptin or glimepiride to ongoing metformin to treat T2DM….

Exenatide yields beta cell improvement and weight loss in individuals with diabetes but has not been well-studied in individuals with prediabetes….

This randomized, open-label, parallel-group, multicenter, 24-wk main treatment study, followed by a variable extension of at least 52 wk, compared the efficacy and safety of lixisenatide 20 µg QD and exenatide 10 µg BID in 634 T2DM patients insufficiently controlled on metformin ≥1.5 g/day (mean age 57.4 yr, diabetes duration …

The cardiovascular (CV) benefit of glucose lowering, particularly if too intensive, in type 2 diabetes mellitus (T2DM) is currently debated. Some modalities have even been reported, unexpectedly, to be associated with worse CV outcomes. To investigate the CV profile of the novel DPP-4 inhibitor linagliptin, a pre-specified meta-analysis of all …